It is staggering what a pharmaceutical company will pay for the right drug.Abbvie has paid 21$ billion
for pharmacyclics drug Imbruvica.
Imbruvica is a kinase inhibitor which slows down the proliferation of malignant B cells.
Its use is primarily for CLL[CHR LYMPHOCYTIC LEUKAEMIA] and rare forms of non hodgkins lympomas.
The haematology oncology market is estimated to be worth 24$ billion/annum.
It is projected Imbruvica sales will be worth 6$ billion by 2020.
It will be interesting to see what a pharma will be prepared to pay for Viralytics once all the data is in showing cavatek is effective in combo across a broad spectrum of cancers.
VLA Price at posting:
42.5¢ Sentiment: Buy Disclosure: Held
